EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors

Filippo Ghelardi, Giovanni Fucà, Chiara Cavalli, Kohei Shitara, Romain Cohen, Margherita Ambrosini, Steven B Maron, Riccardo Cerantola, Vincenzo Nasca, Giorgia Di Liberti, Luca Zambelli, Michele Palazzo und 8 weitere

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2024.05.005 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Filippo Ghelardi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Microsatellite Instability, Stomach Neoplasms, Nutrition Assessment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Microsatellite instability high (MSI-H) and/or mismatch repair deficient (dMMR) status is the strongest predictive factor for immune checkpoint inhibitors (ICIs) benefit in patients with metastatic gastroesophageal cancer (mGC). Primary resistance to ICIs is a relevant issue, but prognostic and predictive factors are lacking. MATERIALS AND METHODS: In this multinational, retrospective cohort of patients with MSI-H/dMMR mGC treated with ICIs without chemotherapy we collected baseline laboratory values to establish the prognostic nutritional index (PNI). We evaluated the association between baseline PNI with the activity and efficacy of ICIs. RESULTS: At a median follow-up of 31.6 months, median progression-free survival (PFS) and 2-year PFS rate were not reached and 73.6 % in the PNI-high subgroup versus 6.3 months and 38.3 % in the PNI-low one (HR 0.32, 95 % CI: 0.16-0.61, p < .001). Median overall survival (OS) and 2-year OS rate were not reached and 81.9 % in the PNI-high subgroup versus 24.4 months and 50.5 % in the PNI-low one (HR 0.26, 95 % CI: 0.12-0.56, p < .001). In multivariable models, high PNI was associated with longer PFS and OS (HR 0.30, 95 % CI: 0.15-0.61, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMicrosatellite InstabilityStomach NeoplasmsNutrition AssessmentEsophageal NeoplasmsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedPrognosisAdultProgression-Free SurvivalAged, 80 and overDNA Mismatch Repair

Stichwörter der Autor:innen

Gastric cancerImmune checkpoint inhibitorsMsi-hNutritional statusPrognostic factors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Sorbonne Université, INSERM, Unité Mixte de Recherche Scientifique 938 and SIRIC CURAMUS, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale con…
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; PhD Program Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.

Förderung

  • Ministero della Salute
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Ghelardi, F., Fucà, G., Cavalli, C., Shitara, K., Cohen, R., Ambrosini, M., Maron, S. B., Cerantola, R., Nasca, V., Liberti, G. D., Zambelli, L., Palazzo, M., Salati, M., Aoki, Y., Kawazoe, A., Cowzer, D., Lonardi, S., André, T., Randon, G., & Pietrantonio, F. (2025). The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.05.005

Vancouver

Ghelardi F, Fucà G, Cavalli C, Shitara K, Cohen R, Ambrosini M, et al. The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2024.05.005

BibTeX
@article{Ghelardi2025,
  author = {Ghelardi, Filippo and Fucà, Giovanni and Cavalli, Chiara and Shitara, Kohei and Cohen, Romain and Ambrosini, Margherita and Maron, Steven B and Cerantola, Riccardo and Nasca, Vincenzo and Liberti, Giorgia Di and Zambelli, Luca and Palazzo, Michele and Salati, Massimiliano and Aoki, Yu and Kawazoe, Akihito and Cowzer, Darren and Lonardi, Sara and André, Thierry and Randon, Giovanni and Pietrantonio, Filippo},
  title = {The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2024.05.005}
}
Kostenlos starten →